Logo

Seraseq Circulating Tumor DNA v2 Reference Materials

Jul 18, 2017

SeraCare Life Sciences has launched a new set of ctDNA reference materials to aid development and validation of liquid biopsy assays. The new Seraseq Circulating Tumor DNA v2 reference materials were produced using a unique technology that produces a DNA fragment size-distribution which closely mimics native cfDNA, while decreasing DNA damage relative to ultrasonicated material, the company said.

The new product requires no special workflow considerations to generate informative data, and contains 40 somatic mutations, including important targets like BRAF V600E, KRAS G12D, and various EGFR alterations. Variants are present against a single well-characterized genomic background across a range of allele frequencies down to 0.125 percent, which ensures utility for assays with different limits of detection.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.